氟伐他汀干预治疗对不稳定性心绞痛患者介入治疗后炎症因子影响的研究

被引：26

作者：

沈青山

刘永胜

朱锐

付度关

汤永谦

陶红

李素珍

叶剑文

机构：

[1] 湖北省襄樊市中心医院心内科

[2] 湖北省襄樊市中心医院心内科襄樊

[3] 襄樊

来源：

中华心血管病杂志 | 2005年 / 04期

关键词：

心绞痛; 脂类和降血脂药; 血管成形术,经腔,经皮冠状动脉; C反应蛋白质; 肿瘤坏死因子;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的　研究氟伐他汀对不稳定性心绞痛冠状动脉介入(PCI)治疗术患者高敏C -反应蛋白(hs- CRP)、肿瘤坏死因子α(TNFα)和肌钙蛋白I(cTnI)的影响。方法　选择2002年7月至2004年4月在我院行冠状动脉介入术的60例不稳定性心绞痛患者为研究对象,随机分为二组:对照组29例,常规药物治疗(抗凝、硝酸酯类、β受体阻断剂、血管紧张素转换酶抑制剂和钙拮抗剂等) 2周;氟伐他汀干预组31例,在常规治疗基础上加用氟伐他汀(商品名来适可)每日40mg治疗2周。分别于药物治疗前、药物治疗后2周(术前当天)及术后24h采集空腹静脉血,测定血清hs -CRP、TNFα和cTnI浓度。结果　药物治疗后,氟伐他汀干预组较对照组血清hs CRP、TNFα和cTnI浓度降低更明显(P<0 .01);氟伐他汀干预组术后血清hs- CRP、TNFα和cTnI浓度明显低于同期对照组(P<0. 01)。结论　冠状动脉介入术后增加血清hs- CRP、TNFα和cTnI水平;氟伐他汀降低冠心病患者血清hs -CRP、TNFα和cTnI浓度;氟伐他汀降低冠状动脉介入术后患者血清CRP、TNFα和cTnI水平。

引用

页码：320 / 322

页数：3

共 8 条

[1]

Immediate and late outcomes after direct stent implantation without ballon predilation. Wilson SH,Berger PB,Mathew V,et al. Journal of the American College of Cardiology . 2000

[2]

Clinicaloutcome10yearsafterattemptedpercutaneoustransluminalcoronaryangioplasty in856patients. RuygrokPN,deJaegerePT,vanDomburgRT,etal. Journal of the American College of Cardiology . 1996

[3]

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Serruys P-W,de Feyter P,Macaya C,et al. The Journal of The American Medical Association . 2002

[4]

PreventionofcardiovasculareventsanddeathwithPravastatininpatientswithcoronaryheartdiseaseandabroadrangofinitialcholesterollevels.TheLong termInterventionwithPravastatininIschemicDisease(LIPID)StudyGroup. The New England Journal of Medicine . 1998

[5]

Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty ( REGRESS trial). Mulder HJ,Bal ET,Jukema JW,et al. The American Journal of Cardiology . 2000

[6]

A randomized placebocontrolled trial of fluvastatin for prevention of restenosis after successful coronary ballon angioplasty: final results of the fluvastatin angiographic restenosis ( FLARE) trial. Serruys PW,Foley DP,Jackson G,et al. European Heart Journal . 1999

[7]

Cardiac enzyme elevation after percutaneous coronary intervention: myonecrosis, the coronary microcirculation and mortality. Harrington RA. Journal of the American College of Cardiology . 2000

[8]

Cardiac troponin T and CKMB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Ravkilde J,Nissen H,Mickley H,et al. American Heart Journal . 1994

← 1 →